Kairos Pharma (NYSEAMERICAN:KAPA) Announces Quarterly Earnings Results

Kairos Pharma (NYSEAMERICAN:KAPA) released its quarterly earnings data on Wednesday. The company reported ($0.06) earnings per share for the quarter, FiscalAI reports.

Kairos Pharma Trading Down 3.1%

KAPA traded down $0.01 during midday trading on Friday, hitting $0.35. 135,892 shares of the company were exchanged, compared to its average volume of 1,112,546. The company’s 50 day simple moving average is $0.37 and its 200 day simple moving average is $0.51. The firm has a market capitalization of $7.47 million, a price-to-earnings ratio of -1.25 and a beta of 1.56. Kairos Pharma has a 1-year low of $0.27 and a 1-year high of $2.11.

Institutional Trading of Kairos Pharma

A hedge fund recently bought a new position in Kairos Pharma stock. XTX Topco Ltd purchased a new stake in shares of Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 62,746 shares of the company’s stock, valued at approximately $44,000. XTX Topco Ltd owned approximately 0.31% of Kairos Pharma at the end of the most recent quarter.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical?stage biopharmaceutical company focused on developing small?molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full?length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.